Prognostic value of hematological parameters in patients undergoing esophagectomy for esophageal squamous cell carcinoma by unknown
1 3
Int J Clin Oncol (2016) 21:909–919
DOI 10.1007/s10147-016-0986-9
ORIGINAL ARTICLE
Prognostic value of hematological parameters in patients 
undergoing esophagectomy for esophageal squamous cell 
carcinoma
Noriyuki Hirahara1 · Takeshi Matsubara1 · Daisuke Kawahara1 · Yoko Mizota1 · 
Shuichi Ishibashi1 · Yoshitsugu Tajima1 
Received: 30 November 2015 / Accepted: 25 April 2016 / Published online: 6 May 2016 
© The Author(s) 2016. This article is published with open access at Springerlink.com
patients after curative esophagectomy. Furthermore, in 
non-elderly patients, a high RDW was a significant and 
independent predictor of poor survival.
Keywords Esophageal cancer · Red cell distribution width 
(RDW) · Prognostic predictor
Introduction
Recent studies have shown that preoperative inflammation-
based prognostic scores can predict the overall survival of 
patients with various cancers [1–3]. The systemic inflam-
matory response is associated with immune and coagu-
lation processes, although the precise mechanisms that 
underlie this response, as well as the interaction between 
coagulation, inflammation, and carcinogenesis remain 
obscure.
The red blood cell distribution width (RDW) is the coef-
ficient of variation in red blood cell size, and an elevated 
RDW corresponds to anisocytosis [4]. Although its main 
clinical application has been limited to the diagnosis of 
iron deficiency anemia, fluctuations in RDW have recently 
been reported in many pathophysiological conditions, and 
elevated RDW is strongly associated with chronic inflam-
mation, poor nutritional status, and age-associated diseases 
via changes in erythropoiesis. Cancer is known to evoke 
chronic inflammation and malnutrition, and cancer-associ-
ated inflammation is a key determinant of disease progres-
sion and survival in various cancers [5, 6].
Mean platelet volume (MPV), a marker of platelet size, 
is a platelet volume index and reflects early platelet acti-
vation [7]. An elevated MPV is closely associated with 
thromboembolism in patients with ischemic stroke, myo-
cardial infarction, and cerebrovascular thromboembolism 
Abstract 
Background It is now widely recognized that outcomes in 
cancer patients are not determined by their tumor charac-
teristics alone. In this study, we retrospectively analyzed 
the clinical data of esophageal cancer patients to evaluate 
the impact of red blood cell distribution width (RDW), 
platelet distribution width (PDW), and mean platelet vol-
ume (MPV) on cancer-specific survival (CSS).
Study design We retrospectively reviewed a database 
of 144 consecutive patients who underwent curative 
esophagectomy for esophageal squamous cell carcinoma at 
our institute between 2006 and 2014.
Result In multivariate analysis, pathological stage (pStage) 
(p = 0.0002) and a high RDW (p = 0.0300) were found 
to be independently associated with poor survival. Patients 
with a high RDW had a significantly poorer prognosis in 
terms of CSS than those with a low RDW (p = 0.004).
Among non-elderly patients, multivariate analysis dem-
onstrated that pStage (p = 0.0120), and a high RDW 
(p = 0.0092) were independent risk factors for a worse 
prognosis. In addition, non-elderly patients with a high 
RDW had a significantly poorer prognosis in terms of CSS 
than those with a low RDW (p = 0.0003).
On the other hand, univariate analysis demonstrated that 
pStage (p = 0.0008) was the only significant risk factor for 
a poor prognosis in elderly patients.
Conclusions We confirmed that a high RDW was sig-
nificantly associated with the CSS of esophageal cancer 
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[8–10]. In addition, platelets have an inflammatory role 
that is mediated by the secretion of pro-inflammatory fac-
tors, chemokines, and growth factors. They also have a 
role in cancer progression. Consequently, an inflammatory 
response significantly increases the risk of metastases at 
each cancer stage, and thus these hematological parameters 
predict a poor prognosis in, for example, gastric, lung, and 
renal cancer [11–13].
Another indicator of platelet morphology is the plate-
let distribution width (PDW). PDW is a measure of vari-
ation in platelet size, and a high PDW can be a sign of 
active platelet release. The induction of platelet production 
leads to an increase in the average platelet size and conse-
quently affects the PDW. Furthermore, an elevated platelet 
count and increased platelet aggregation have been shown 
to facilitate tumor progression by protecting tumor cells 
from the immune system [14]. PDW is therefore a potential 
prognostic indicator in cancer, although it should be noted 
that both PDW and MPV can also change in a number of 
benign conditions [15, 16].
It is now widely recognized that outcomes in cancer 
patients are not determined by their tumor characteristics 
alone, but also by non-tumor factors such as their general 
health [17]. There is a growing interest in establishing 
novel predictive biomarkers for various cancers. However, 
to the best of our knowledge, there has been no direct anal-
ysis of the predictive value of RDW, PDW, and MPV indi-
ces in esophageal cancer. In this study, we retrospectively 
analyzed the clinical data of esophageal cancer patients to 




We retrospectively reviewed a database of 144 consecutive 
patients who underwent potentially curative esophagec-
tomy with R0 resection for histologically verified esopha-
geal squamous cell carcinoma at our institute between Jan-
uary 2006 and December 2014. R0 resection was defined 
as a complete resection without any microscopic resec-
tion margin involvement. Video-assisted or thoracoscopic 
esophagectomy with three-field lymph node dissection 
was performed for all patients, followed by elevation of 
the gastric conduit to the neck via the posterior mediastinal 
approach or the retrosternal approach with end-to-end anas-
tomosis of the cervical esophagus and the gastric conduit. 
The clinical characteristics, laboratory data, treatment, and 
pathological data for the patients were obtained from their 
medical records. No patient had clinical signs of infection 
or other systemic inflammatory conditions preoperatively.
We evaluated the CSS, in which the cause of death was 
determined from the case notes or computerized records. 
Two patients who died of a complication related to surgery 
within 60 days after esophagectomy were excluded from 
the analysis. We defined ‘elderly’ patients as those aged 
≥70 years and ‘non-elderly’ as those aged <70 years [3].
The observation period started from the day of the oper-
ation and lasted for 5 years or until death, loss to follow-up, 
or withdrawal of consent.
Permission to perform this retrospective study was 
obtained from the ethical board of our institution.
Blood sample analysis
Preoperative complete blood count (CBC) data were retro-
spectively extracted from the medical records. Only sub-
jects for whom preoperative CBC and blood differential 
data were available were included in the study. All white 
blood cell and differential counts were taken within 1 week 
prior to surgery.
RDW, PDW, and MPV
CBC and hematological marker levels were measured 
using ethylenediaminetetraacetic acid-treated blood. Blood 
parameters, RDW, PDW, and MPV were analyzed using 
an automated hematology analyzer XE-5000 (Sysmex 
XE-5000 hematology analyzer; TOA Medical Electronics, 
Kobe, Japan). RDW, PDW, and MPV values were obtained 
directly from the CBC tests.
TNM stage
The pathological classification of the primary tumor, the 
degree of lymph node involvement, and the presence of 
organ metastasis were determined according to the TNM 
classification system in the 7th edition of the Cancer Staging 
Manual of the American Joint Committee on Cancer [18].
Statistical analysis
The means and standard deviations were calculated, and 
the differences were analyzed using Student’s t test. Differ-
ences between categories of each clinicopathological fea-
ture were analyzed using the chi-squared test. The routine 
reference cut-off values for RDW, PDW, and MPV used by 
our hospital laboratory were <50, <15.3, and <11.5, respec-
tively. Patients with a RDW, PDW, or MPV greater than 
these cut-off values were considered to have a high RDW, 
PDW, and MPV, while the remaining patients were con-
sidered to have a low RDW, PDW, and MPV, respectively. 
The CSS was calculated using Kaplan–Meier statistics, and 
inter-group differences were assessed using the log-rank 
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test. CSS was defined as the interval from the date of oper-
ation to the date of cancer specific death, or last follow-up.
Univariate analyses were performed to determine vari-
ables associated with CSS. Variables with p values <0.05 
in the univariate analysis were included in a multivariate 
logistic regression analysis. The potential prognostic fac-
tors for esophageal cancer were age (<70 vs ≥70 years), sex 
(female vs male), pathological stage (pStage; I/II vs III), 
tumor size (<3 cm vs ≥3 cm), operation time (<600 min 
vs ≥600 min), intraoperative blood loss (<500 mL vs 
≥500 mL), serum squamous cell carcinoma antigen (SCC) 
value (<1.5 vs ≥1.5), RDW (<50 vs ≥50), PDW (<15.3 vs 
≥15.3), and MPV (<11.5 vs ≥11.5).
All statistical analyses were performed using the statisti-
cal software JMP (version 11 for Windows; SAS Institute, 
Cary, NC, USA), and p values <0.05 were considered sta-
tistically significant.
Results
Relationships between RDW, PDW, MPV, 
and clinicopathological features
The relationships between RDW, PDW, MPV, and the clin-
icopathological features of 144 esophageal cancer patients 
are shown in Table 1. The mean and standard deviation of 
RDW, PDW, and MPV was 48.6 ± 6.9, 11.3 ± 1.9, and 
10.1 ± 0.9, respectively. Standard values of these param-
eters were different by measuring instrument. The routine 
reference cut-off values for RDW, PDW, and MPV used by 
our hospital laboratory were <50, <15.3, and <11.5, respec-
tively. Patients with a RDW, PDW, or MPV greater than 
these cut-off values were considered to have a high RDW, 
PDW, and MPV, while the remaining patients were consid-
ered to have a low RDW, PDW, and MPV, respectively.
There was a significant association between RDW and 
factors such as tumor location (p = 0.039), tumor depth 
(p < 0.0001), pStage (p = 0.006), and intraoperative blood 
loss (p = 0.024). The PDW also showed significant asso-
ciations with tumor size (p = 0.043), lymph node metas-
tasis (p = 0.0002), and pStage (p = 0.032). No significant 
associations were found between these clinicopathological 
features and MPV.
Prognostic factors for CSS
In this study, we did not analyze the relationship between 
PDW, MPV and prognostic value, because the size of the 
high PDW (n = 4) and the high MPV (n = 12) subgroup 
populations were too small to be compared with another 
group (n = 132).
Univariate analyses demonstrated that pStage (haz-
ard ratio [HR] 4.467; 95 % confidence interval [CI] 
2.469–8.337; p < 0.0001), tumor size (HR 3.172; 95 % CI 
1.511–7.076; p = 0.002), operation time (HR 0.497; 95 % 
CI 0.275–0.888; p = 0.018), and a high RDW (HR 2.332; 
95 % CI 1.304–4.190; p = 0.005) were significant risk fac-
tors for a poor prognosis (Table 2). In multivariate analy-
sis, pStage (HR 3.362; 95 % CI 1.772–6.643; p = 0.0002) 
and a high RDW (HR 1.684; 95 % CI 0.929–3.071; 
p = 0.0300) were found to be independently associated 
with poor survival.
RDW, PDW, MPV, and CSS
We excluded analysis of PDW and MPV because the num-
ber of patients in the high PDW and MPV subgroups was 
too small to show the correct data.
Patients with a high RDW had a significantly poorer 
prognosis in terms of CSS than those with a low RDW 
(p = 0.004) (Fig. 1).
Relationships between RDW, PDW, MPV, 
and clinicopathological features in non‑elderly patients
Significant associations were found between the RDW and 
factors such as tumor location (p = 0.022), tumor depth 
(p < 0.0001), pStage (p = 0.017), and intraoperative blood 
loss (p = 0.044) (Table 3), whilst the PDW only showed 
a significant association with lymph node metastasis 
(p = 0.008). None of the clinicopathological features were 
significantly associated with MPV.
Prognostic factors for CSS in non‑elderly patients
Because the total number of non-elderly patients was small, 
we excluded analysis of PDW and MPV.
Among non-elderly patients, univariate analysis dem-
onstrated that pStage (HR 4.395; 95 % CI 2.059–9.933, 
p = 0.0001), tumor size (HR 5.275; 95 % CI 1.849–22.162; 
p = 0.0009), and a high RDW (HR 3.654; 95 % CI 1.716–
8.241; p = 0.0007) were significantly associated with a 
worse prognosis (Table 4). Multivariate analysis dem-
onstrated that pStage (HR 2.775; 95 % CI 1.247–6.617; 
p = 0.0120), and a high RDW (HR 2.759; 95 % CI 1.282–
6.284; p = 0.0092) were independent risk factors for a 
worse prognosis in non-elderly patients.
RDW and CSS in non‑elderly patients
Non-elderly patients with a high RDW had a significantly 
poorer prognosis in terms of CSS than those with a low 
RDW (p = 0.0003) (Fig. 2).
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Relationships between RDW, PDW, MPV 
and clinicopathological features in elderly patients
There was a significant relationship between RDW and 
operation time (p = 0.015) (Table 5), and between PDW 
and lymph node metastasis (p = 0.022). However, there 
were no significant associations between any of the clinico-
pathological features and MPV.
Prognostic factors for CSS in elderly patients
Because the total number of elderly patients was small, we 
excluded analysis of PDW and MPV.
Univariate analysis demonstrated that pStage 
(p = 0.0008) was the only significant risk factor for a poor 
prognosis in elderly patients (Table 6). RDW showed no 
significant association with postoperative CSS in elderly 
patients (p = 0.664) (Fig. 3).
Discussion
Esophageal cancer is primarily a disease of the elderly, 
with a peak in incidence in the eighth decade of life, and 
the elderly population is rapidly increasing worldwide 
[19]. Despite recent advances in early detection, surgical 
techniques, and chemoradiation therapies, the prognosis of 
esophageal cancer remains poor. Surgery is the mainstay of 
treatment for this malignancy, but a considerable propor-
tion of patients with advanced esophageal cancer develop 
recurrence, even after curative resection. Therefore, reliable 
prognostic factors that permit more accurate patient strati-
fication are needed to improve clinical decision making 
for this malignancy. In addition, esophageal cancer is the 
eighth most common incident cancer and sixth most com-
mon cause of cancer death worldwide [20]. It occurs pre-
dominantly in elderly people, the average age at the time 
of diagnosis continues to rise, with a peak in incidence 
between 70 and 75 years of age [21]. CSS is an impor-
tant outcome measure in elderly patients, as they are more 
likely to die from other age-related diseases such as cardi-
ovascular, renal, and pulmonary diseases. As few patients 
actually died from causes other than cancer in this analysis, 
the data had a limited impact on overall survival. In addi-
tion we divided the patients into two groups in order to cal-
culate the tendency of prognostic value by age, because the 
correlation between prognostic value and age was unknown 
until now.
RDW, which is a measure of heterogeneity in erythro-
cyte size, is routinely examined as part of the CBC test. In 
the development of iron deficiency, an elevated RDW usu-
ally precedes other blood abnormalities, such as a low red 
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and low hemoglobin levels [22]. Furthermore, RDW is a 
more sensitive screening marker for iron deficiency than 
serum ferritin level, transferrin saturation, or serum iron 
level [23]. Since the variability of RBC size increases 
before overt anemia, elevated RDW is a sensitive and spe-
cific indicator of early iron deficiency. In this study, we 
investigated the relationship between hematological param-
eters and CSS in esophageal cancer patients. Among these 
hematological parameters, we included RDW as a marker 
of several conditions including anemia, inflammation, and 
early nutritional deficiencies [24]. Univariate and multivari-
ate analyses demonstrated that a high RDW was indepen-
dently associated with poor prognosis in esophageal cancer 
patients. These findings reflect the widely accepted hypoth-
esis that cancer is both a cause and a result of chronic 
inflammation [25, 26].
Our findings also reveal that a high RDW is poten-
tially an independent risk factor for a worse prognosis in 
non-elderly patients, but not in elderly patients. This was 
unexpected, but could reflect the prevalence of anemia and 
malnutrition in the latter. This would in turn lead to an ele-
vated RDW, which would reduce its prognostic significance 
for cancer in elderly patients.
Platelets play a key role in the coagulation cascade. 
They also release growth factors that can contribute to 
tumor progression and metastasis, in part by mediating 
immunosuppression [16]. Changes in platelet count and 
platelet function have been identified as part of a paraneo-
plastic syndrome in many cancers [27], and a high platelet 
count was found to be closely associated with TNM stage, 
metastasis, and a high risk of recurrence in many types of 
cancer [28, 29]. Platelets release angiogenic growth factors, 
adhere to tumor microvessels, and undergo extravasation 
via increased vascular permeability, a process that leads to 
platelet activation. Increased platelet production is asso-
ciated with bigger platelets, which could affect the PDW, 
and thus the PDW in turn may predict clinical outcome in 
cancer patients. However, to the best of our knowledge, 
the relationship between PDW and esophageal cancer has 
not yet been clarified. We therefore focused on PDW and 
CSS in esophageal cancer patients. However, we could not 
analyze the relationship between PDW and prognostic fac-
tors, because only a small proportion of patients had an ele-
vated PDW, and it had a weak predictive value for clinical 
outcome. Further study of the predictive value of PDW is 
needed with a larger number of patients.
MPV is a platelet volume index and an early marker of 
platelet activation [1]. Elevated MPV is closely associated 
with the severity and prognosis of malignant tumors, as 
well as ischemic cardiovascular disorders [30]. Neoplasms 
are usually accompanied by thrombocytosis, which may 
lead to an elevated MPV and hence an increased risk of 
metastasis and a poor prognosis, as the tumor can produce 
or stimulate the production of cytokines including inter-
leukins, interferon-, and tumor necrosis factor [31]. How-
ever, the prognostic effect of MPV has not been clarified in 
esophageal cancer patients after curative resection. There-
fore, we focused on MPV and CSS in esophageal cancer 
Table 2  Prognostic factors for cancer-specific survival in 144 patients with esophageal cancer after a curative esophagectomy
Variables Patients (n = 144) Category or characteristics Univariate Multivariate
HR 95 % CI p value HR 95 % CI p value
Gender 15/129 (Female/male) 1.209 0.460–2.642 0.672
Age (years) 47/97 (<70/≥70) 1.638 0.889–2.943 0.112
pStage 90/54 (I, II/III) 4.467 2.469–8.337 <0.0001 3.362 1.772–6.643 0.0002
Tumor size 45/99 (<3/≥3) 3.172 1.511–7.076 0.002 1.657 0.722–4.290 0.2427
Operation time 52/92 (<600/≥600) 0.497 0.275–0.888 0.018 0.634 0.348–1.145 0.1303
Intraoperative blood loss 71/73 (<500/≥500) 1.066 0.596–1.924 0.830
SCC value 112/32 (<1.5/≥1.5) 1.468 0.707–2.820 0.288
RDW 94/50 (<50/≥50) 2.332 1.304–4.190 0.005 1.684 0.929–3.071 0.0300






















94 73 54 46 41 28RDW<50
RDW ≥50 50 33 26 19 15 11
Fig. 1  Postoperative cancer-specific survival based on RDW in 144 
patients with esophageal cancer
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Table 3  Relationships between RDW, PDW, MPV, and clinicopathological features in 97 non-elderly patients with esophageal cancer






<50 (n = 61) ≥50 (n = 36) p value 15.3< (n = 95) ≥15.3 (n = 2) p value 11.5< (n = 90) ≥11.5 (n = 7) p value
Age (years) 61.6 ± 5.5 61.2 ± 5.5 0.353 61.3 ± 5.5 66.5 ± 3.5 0.191 61.3 ± 5.5 63.0 ± 5.1 0.22
Gender 0.805 0.648 0.636
 Male 88 55 33 86 2 82 6




 Ce 4 0 4 4 0 4 0
 Ut 5 3 2 5 0 4 1
 Mt 49 28 21 47 2 46 3
 Lt 30 22 8 30 0 28 2
 Ae 9 8 1 9 0 8 1
Tumor size 
(mm)




 Negative 37 12 49 0 46 3




 Negative 37 9 46 0 43 3




 Well 28 2 30 0 28 2
 Moderate 31 27 57 1 54 4




 T1a–1b 43 39 4 43 0 39 4
 2 6 1 5 6 0 6 0
 3 37 18 19 36 1 36 1




 N0 54 35 19 54 0 50 4
 N1 28 17 11 28 0 27 1
 N2 6 3 3 5 1 5 1




 1a–1b 39 31 8 39 0 36 3
 2a–2b 21 12 9 21 0 20 1
 3a–3c 37 18 19 35 2 34 3
Operation 
time (min)




545.8 ± 515.5 736.9 ± 549.1 0.044 619.5 ± 535.7 485.0 ± 558.6 0.726 612.3 ± 531.8 674.3 ± 596.0 0.769
SCC value 1.14 ± 1.17 0.96 ± 0.67 0.803 1.06 ± 1.02 1.55 ± 0.35 0.504 1.09 ± 1.04 0.81 ± 0.60 0.485
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patients but could not analyze the relationship between 
MPV and prognostic factor. As we determined the cut-off 
values for RDW, PDW, and MPV to our routine labora-
tory data, the number of patients in the high MPV group 
(n = 12) was too small to compare with another group 
(n = 132), similar to PDW. Unfortunately, in this study we 
could not evaluate the prognostic value of MPV. Although 
platelet count is closely related to a variety of pathophysi-
ological conditions, such as myocardial infarction, stroke, 
chronic inflammation, and poor nutrition, these conditions 
are frequently found in the elderly regardless of whether 
they have cancer [32, 33]. Furthermore, platelets are known 
to facilitate tumor progression by protecting them from 
immune responses. The present study may have failed to 
demonstrate a prognostic significance for MPV and PDW, 
because the number of patients was too small to evalu-
ate the prognostic value for esophageal cancer. However, 
several clinical studies have demonstrated that MPV was 
elevated in patients with various carcinomas, although 
other studies have contradicted this [11, 34]. Further inves-
tigations are required to elucidate the precise mechanisms 
through which circulating platelets affect the prognosis of 
esophageal cancer patients.
In this study, we confirmed that the RDW was associ-
ated with the CSS of esophageal cancer patients after 
curative esophagectomy. It is particularly noteworthy that 
a high RDW was a significant and independent predictor 
of poor survival. Furthermore, in non-elderly patients, a 
high RDW was also an independent risk factor for a worse 
prognosis. We showed that a high RDW was associated 
with poor survival; the mean RDW was 48.6 ± 6.9 in this 
analysis. A high RDW may by correlated with tumor depth 
and pathological stage in advanced-staged esophageal can-
cer patients. However, this study was retrospective analysis 
with a small sample size. As the RDW is convenient, cost-
effective and readily available as part of the routine CBC, it 
could act as a marker of survival in this malignancy. Thus, 
larger prospective studies are needed to confirm these pre-
liminary results.
It is important to explore the risk factors for postop-
erative complications after esophagectomy, because they 
are more likely to cause complications when comparing 
esophagectomy with other gastrointestinal surgery. How-
ever, we could not demonstrate the predictive significance 
of RDW, PDW, and MPV of postoperative complica-
tion risks in this study (data not shown). We think this is 
because many of the patients with esophageal cancer had 
preoperative complications. In addition, we observed many 
patients who showed a high RDW after recurrence. How-
ever, we were unable to demonstrate a relationship efficacy 
between chemoradiotherapy and RDW, PDW or MPV after 
recurrence. Further studies are warranted to confirm the 
changes in before and after surgery effects after recurrence.
In conclusion, we confirmed that a high RDW was asso-
ciated with the CSS of esophageal cancer patients after 
curative esophagectomy. However, a number of potential 
study limitations need to be taken into consideration. The 
cut-off value should be set by ROC analysis rather than by 
routine laboratory value in the data analysis. However, we 
performed analysis by routine laboratory values because 
the correct cut-off values of RDW, MPV, and PDW were 
Table 4  Prognostic factors for cancer-specific survival in 97 non-elderly patients with esophageal cancer after a curative esophagectomy
Variables Patients (n = 97) Category or characteristics Univariate Multivariate
HR 95 % CI p value HR 95 % CI p value
Gender 9/88 (Female/male) 0.526 0.202–1.794 0.272
pStage 60/37 (I, II/III) 4.395 2.059–9.933 0.0001 2.775 1.247–6.617 0.012
Tumor size 33/64 (<3/≥3) 5.275 1.849–22.162 0.0009 2.716 0.862–12.018 0.0919
Operation time 34/63 (<600/≥600) 0.487 0.228–1.027 0.059
Intraoperative blood loss 46/51 (<500/≥500) 1.415 0.670–3.116 0.365
SCC value 76/21 (<1.5/≥1.5) 1.051 0.351–2.575 0.92
RDW 61/36 (<50/≥50) 3.654 1.716–8.241 0.0007 2.759 1.282–6.284 0.0092






















61 50 40 35 33 21RDW<50
RDW ≥50 36 24 20 15 13 9 
Fig. 2  Postoperative cancer-specific survival based on RDW in 97 
non-elderly patients with esophageal cancer
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Table 5  Relationships between RDW, PDW, MPV, and clinicopathological features in 47 elderly patients with esophageal cancer
Ce cervical esophagus, Ut upper thoracic esophagus,  Mt middle thoracic esophagus, Lt lower thoracic esophagus, Ae abdominal esophagus
Character-
istics
Total patients RDW PDW MPV
<50 (n = 33) ≥50 (n = 14) p value <15.3 (n = 45) ≥15.3 (n = 2) p value <11.5 (n = 42) ≥11.5 (n = 5) p value
Age (years) 75.1 ± 4.4 75.6 ± 4.2 0.634 75.3 ± 4.4 73.0 ± 2.8 0.461 75.4 ± 4.5 73.8 ± 2.3 0.781
Gender 0.088 0.107 0.054
 Male 41 27 14 40 1 38 3




 Ce 1 1 0 1 0 1 0
 Ut 6 3 3 6 0 5 1
 Mt 17 12 5 17 0 15 2
 Lt 21 15 6 19 2 19 2
 Ae 2 2 0 2 0 2 0
Tumor size 
(mm)




 Negative 18 8 26 0 24 2




 Negative 14 6 20 0 18 2




 Well 12 5 17 0 15 2
 Moderate 17 8 23 2 22 3




 T1a–1b 20 14 6 20 0 17 3
 2 6 6 0 6 0 6 0
 3 19 13 6 17 2 17 2




 N0 77 18 5 23 0 22 1
 N1 42 8 6 14 0 12 2
 N2 13 5 2 6 1 6 1




 1a–1b 56 14 3 17 0 16 1
 2a–2b 34 9 4 13 0 11 2
 3a–3c 54 10 7 15 2 15 2
Operation 
time (min)




558.1 ± 617.3 907.5 ± 864.4 0.062 670.0 ± 717.7 485.0 ± 615.2 0.722 678.9 ± 730.2 522.0 ± 533.0 0.322
SCC value 1.25 ± 1.15 2.12 ± 4.39 0.145 1.44 ± 2.60 3.00 ± 0.14 0.405 1.50 ± 2.67 1.56 ± 1.36 0.519
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uncertain, and we confirmed survival data using the hema-
tological parameters of our routine laboratory values in 
this analysis. Therefore, these data should be carefully 
interpreted. Furthermore, this was a retrospective, single-
institution design study with a small sample size and short 
follow-up period. Thus, larger prospective studies are 
required to elucidate the precise mechanisms that relate 
RDW, PDW and MPV to survival in esophageal cancer 
patients.
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Table 6  Prognostic factors for cancer-specific survival in 47 elderly patients with esophageal cancer after a curative esophagectomy
Variables Patients (n = 47) Category or characteristics Univariate Multivariate
HR 95 % CI p value HR 95 % CI p value
Gender 6/41 (Female/male) 1.946 0.546–12.390 0.338
pStage 30/17 (I, II/III) 5.303 2.001–15.063 0.0008 5.303 2.001–15.063 0.0008
Tumor size 12/35 (<3/≥3) 1.496 0.535–5.288 0.463
Operation time 18/29 (<600/≥600) 0.54 0.206–1.372 0.193
Intraoperative blood loss 25/22 (<500/≥500) 0.666 0.251–1.709 0.396
SCC value 36/11 (<1.5/≥1.5) 2.139 0.731–5.657 0.156
RDW 33/14 (<50/≥50) 1.243 0.431–3.216 0.669
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Fig. 3  Postoperative cancer-specific survival based on RDW in 47 
elderly patients with esophageal cancer
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